Aldeyra Therapeutics Debt 2024

Aldeyra Therapeutics Aktienanalyse

What does Aldeyra Therapeutics do?

Aldeyra Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies for serious eye and immune system diseases. The company was founded in 2004 by Dr. Tod B. Zimmerman and is headquartered in Lexington, Massachusetts. The history of Aldeyra Therapeutics began with the discovery of a new approach to treating inflammatory diseases. The company identified a new class of compounds known as aldehyde binding agents that help reduce the effects of chronic inflammation. In 2013, Aldeyra went public and raised $15 million to advance the development of its products. Aldeyra Therapeutics' business model focuses on building a portfolio of therapies for serious diseases. The company leverages its expertise in drug discovery, development, and commercialization to develop new therapies targeting rare diseases and unmet clinical needs. Aldeyra Therapeutics is divided into two main areas: ophthalmology and immunology. In the ophthalmology field, the company focuses on developing therapies for the treatment of dry eye, pterygium, conjunctivitis, and other eye diseases. In the immunology field, the company aims to develop therapies for immune-related diseases such as asthma, chronic obstructive pulmonary disease (COPD), autoimmune diseases, and others. One key product of Aldeyra Therapeutics is the drug reproxalap, which was developed to halt the progression of dry eye disease. Reproxalap is an aldehyde binding agent designed to help reduce inflammation, pain, and redness in patients with dry eye. The company plans to conduct further clinical trials for reproxalap to facilitate its submission for approval to the US Food and Drug Administration (FDA). Another product in the immunology field is ADX-1612, an aldehyde binding agent targeting the treatment of asthma. The clinical trials are still in the early phases, but preliminary data provide hope that ADX-1612 could become an important component of asthma therapy in the future. Aldeyra Therapeutics does not work alone. The company has partnerships with other biotech or pharmaceutical companies, such as in the development of therapeutics for rare immunological and eye diseases or the development of diagnostic tests for a specific eye disease. The company hopes that its research and development efforts will ultimately help improve the lives of people with serious diseases. Although there is a risk of setbacks in the development of new therapies, it is hoped that Aldeyra Therapeutics will find new ways in the future to address the unmet needs of patients in need. Aldeyra Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Aldeyra Therapeutics's Debt Structure

Aldeyra Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Aldeyra Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Aldeyra Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Aldeyra Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Aldeyra Therapeutics stock

What is the debt of Aldeyra Therapeutics this year?

Aldeyra Therapeutics has a debt level of -127.68 USD this year.

What was the debt of Aldeyra Therapeutics compared to the previous year?

The debt of Aldeyra Therapeutics has increased by -0.8% compared to the previous year dropped.

What are the consequences of high debt for investors in Aldeyra Therapeutics?

High debt can pose a risk for investors of Aldeyra Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Aldeyra Therapeutics?

Low debt means that Aldeyra Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Aldeyra Therapeutics affect the company?

An increase in debt of Aldeyra Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Aldeyra Therapeutics affect the company?

A reduction in debt of Aldeyra Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Aldeyra Therapeutics?

Some factors that can influence the debt of Aldeyra Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Aldeyra Therapeutics so important for investors?

The debts of Aldeyra Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Aldeyra Therapeutics take to change the debt?

To change the debt, Aldeyra Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Aldeyra Therapeutics pay?

Over the past 12 months, Aldeyra Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aldeyra Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aldeyra Therapeutics?

The current dividend yield of Aldeyra Therapeutics is .

When does Aldeyra Therapeutics pay dividends?

Aldeyra Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aldeyra Therapeutics?

Aldeyra Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aldeyra Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aldeyra Therapeutics located?

Aldeyra Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aldeyra Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aldeyra Therapeutics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Aldeyra Therapeutics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Aldeyra Therapeutics in the year 2023?

In the year 2023, Aldeyra Therapeutics distributed 0 USD as dividends.

In which currency does Aldeyra Therapeutics pay out the dividend?

The dividends of Aldeyra Therapeutics are distributed in USD.